Eli Lilly and Company (LLY)
Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Eli Lilly stock has fallen in the days following the release of its latest earnings numbers.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Eli Lilly a Buy? Analyst Confidence Grows for 2025
Eli Lilly's NYSE: LLY market isn't out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a rally because of underperformance, but the salient details are that growth is robust, driving impressive profits, and is expected to accelerate in 2025.
Unlocking Lilly (LLY) International Revenues: Trends, Surprises, and Prospects
Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
Analysts revise Eli Lilly stock price targets
Eli Lilly (NYSE: LLY), one of the U.S.'s foremost pharmaceutical giants, faced a sharp 8% drop in its stock price after reporting disappointing third-quarter results, erasing nearly $70 billion from its market value.
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects.
Market Movers: 2 Top Dividend Stocks I'm Watching No Matter Who Wins
With the upcoming election sparking volatility, I'm sharing two dividend stocks on my radar. These picks offer reliable growth potential, no matter the political outcome. Each stock has a solid track record of outperformance and strong fundamentals. I'm confident they could deliver stability and compound over time, even through uncertainty. Adding these to my watch list reflects my belief in their resilience and potential. These are stocks I'd consider buying soon, regardless of the election's impact.
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut.
Eli Lilly viewed positively despite Mounjaro, Zepbound disappointment - BoA
Bank of America has stuck by Eli Lilly and Co (NYSE:LLY) despite underwhelming sales of its weight loss and diabetes products Zepbound and Mounjaro in the third quarter. Reiterating a ‘buy' rating, Bank of America noted it remained “positive” on Eli “on weakening manufacturing headwinds and acceleration of on-demand activities”.
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next.
Sales of Zepbound and Mounjaro both missed Wall Street estimates by significant margin.
Buy, Sell, Or Hold LLY Stock At $850?
Eli Lilly stock (NYSE: LLY) fell over 6% on Wednesday, October 30, after it posted downbeat results. The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.
